Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: D2A21 gel - Demegen; Demegel; Peptidyl MIM; Provena

Latest Information Update: 13 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Demegen
  • Developer Demegen; DFB Pharmaceuticals
  • Class Antibacterials; Antineoplastics; Peptide antibiotics
  • Mechanism of Action Apoptosis stimulants; Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Burn infections
  • Preclinical Bacterial infections
  • Discontinued Cancer; Protozoan infections

Most Recent Events

  • 13 Jul 2017 D2A21 is still in Preclinical trials for Bacterial infections in USA (Demegen pipeline, July 2017)
  • 13 Jul 2017 Phase-III clinical trials in Burn infections in USA (Topical) before July 2017 (Demegen pipeline, July 2017)
  • 27 Jun 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top